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Introduction
In 1869, Thomas R. Ashworth, at that time Resident
Physician at Melbourne Hospital, reported the presence
of tumor cells in the blood of a deceased cancer patient
[1] observed under a simple microscope. Half a century
ago, the hypothesis of the systemic character of cancer
enabled the development of chemotherapy to com-
plement local treatments, and the restriction of mutilating
non-curative surgeries, as in the case of Halsted
mastectomy in breast cancer [2]. Now, tumor cells can be
detected in the blood of cancer patients at a concentration
of one cell in 1 mL of blood, by a mixed technique of
immunomagnetic enrichment, flow cytometry and
immunocytochemical analysis [3]. In 1977, Leon et al.
reported the presence of free DNA concentrations
between 2 µg/mL in the serum of diverse neoplastic
diseases, and they related the amount of circulating DNA
with stage and response to treatment [4]. Small amounts
of free DNA circulate in plasma or serum in both healthy
individuals and in diseases other than cancer, but higher
concentrations are present in cancer patients. Median
concentrations of this DNA are reported to be between
24-211 ng/mL in tumor diseases [4, 5]. Tumor cells are
characterized by specific genetic alterations. When such
genetic alterations are identified in body fluids as serum
or plasma, regardless of the presence of detectable tumor
cells, it has been called free-circulating tumor associated
DNA [6]. 
With the improvement of molecular analysis
techniques, several studies have been conducted to detect
the molecular events present in the serum that support
evidence of tumor origin. The most frequent alterations
studied are: microsatellite alterations, expressed as a loss
of heterozygosity (an allelic loss) (LOH) or microsatellite
instability (MI); the presence of mutations in specific
oncogenes or in tumor suppressor genes; and the hyper-
methylations of the promoter regions of different genes.
Microsatellite instability has been identified as one of the
most important mechanisms of carcinogenesis and has
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Tumor-derived genetic changes and epigenetic alterations have been found in the serum and plasma of cancer patients.
The alterations found in the blood mimic the alterations found in the primary tumor with a 71% of similarity. Moreover, these
alterations are not found in normal tissues of healthy controls. These findings have important consequences for the detection,
monitoring, prognosis, and early diagnosis of cancer. In this work, we will revisit anecdotal but repetitive observations of these
possibilities that have been made during the last decade. New studies should be undertaken in order to ascertain the
applicability of these observations, and their use in clinics. Sensitivity and specificity must be improved, and clinical and
epidemiological studies should incorporate this technology to enable proper conclusions.
DNA nowotworu krà˝àce w osoczu/surowicy i jego zastosowania kliniczne
W surowicy i osoczu chorych na nowotwory z∏oÊliwe mo˝na stwierdziç zmiany genetyczne i przemiany epigenetyczne,
wywo∏ane samà obecnoÊcià guza nowotworowego. Przemiany, stwierdzane we krwi, naÊladujà przemiany obecne w pierwotnym
guzie, z ujednoliceniem si´gajàcym 71%. Co wi´cej, przemian tych nie stwierdza si´ w tkankach zdrowych osób badanych
w ramach grup kontrolnych. Zjawiska te majà niebagatelne znaczenie dla wykrywania, monitorowania i okreÊlenia rokowania
w poszczególnych przypadkach raka, jak równie˝ mogà byç istotne przy wczesnym wykrywaniu nowotworów. W niniejszej pracy
omówimy nierzadko anegdotyczne, niemniej jednak powtarzalne zjawiska, które zosta∏y zaobserwowane w ciàgu ostatniego
dziesi´ciolecia. Nale˝y podjàç badania majàce na celu potwierdzenie przydatnoÊci opisanych zjawisk oraz zastosowanie
ich w pracy klinicznej. W celu wyciàgni´cia prawid∏owych wniosków nale˝y przede wszystkim poprawiç czu∏oÊç i specyficznoÊç
wspomnianych parametrów oraz uwzgl´dniç je w badaniach klinicznych i epidemiologicznych.
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first been described in colon cancer [7, 8]. Transcriptional
silencing by methylation of CpG nucleotides containing
the promoter regions of tumor suppressor genes seems
a common characteristic of tumors and is being studied in
various diseases. All of these molecular studies have been
done in DNA obtained either in plasma or in serum. It is
unclear which one better reflects the clinical status. Some
studies have approached this problem. It seems that the
concentration of cell-free genomic DNA in fresh plasma
could be the same as the one found in circulation, and
that serum must be collected with sample tubes without
anticoagulant to allow clot formation [9]. For some
authors, the levels of serum DNA or plasma DNA can be
correlated with some different aspects of diagnosis or
prognosis [10]. For the purpose of this review we will not
differentiate between plasma and serum results, and we
will refer to them indistinctly as s/p DNA.
The study of s/p DNA has opened up numerous
areas of investigation and new possibilities for molecular
diagnosis. We will divide this review into 5 parts: first,
the etiology and origin of circulating free DNA; second,
the similarities of alterations found in s/p DNA and
primary tumor; third, its value as a prognosis tool to
calculate the risk of local or distant recurrence and its
relationship with survival; fourth, its value for follow-up
patients or to evaluate response to therapy; and finally,
the possibility to use it as an early diagnostic tool in an
asymptomatic population.
Etiology
All individuals present circulating DNA in their blood, but
the level of DNA in cancer patients is higher. Only
a fraction of the circulating DNA found in neoplastic
patients is attributed to cancer cells. The presence of
tumor DNA using nucleic acid-base molecular analysis
has been found in samples of ascites in ovarian cancer
[11], stools in curable colorectal cancer [12], urine in
bladder cancer [13], and sputum in lung cancer[14]. This
has been attributed to a direct shedding of cells to stools
in the case of colorectal primaries, or to sputum in the
case of lung cancer etc.
The presence of nucleic acids in plasma and serum of
neoplastic patients that harbor the same primary tumor-
derived genetic or epigenetic alterations and viral nucleic
acids has been related to the presence of tumor cells in
the blood. These cells could be normal cells that have
left the primary tumor but are still unable to metastasize
to new organs, or they could be nonviable (apoptotic)
neoplastic cells released as a consequence of anaplasia
and necrosis of aggressive tumors. However, the
possibility of the active shedding of DNA in the blood
by malignant cells has also been suggested [15]. A recent
study of 30 unselected cancer patients ruled out the
possibility of lymphocyte DNA or degeneration of
endothelial cells as origins of s/p DNA. The authors
concluded that non-tumor DNA originates from normal
cells that surround the tumor tissue, which are
degenerated by the growing tumor, and that the soluble
DNA in the form of chromatin fragments is released from
apoptotic and necrotic cells. Therefore, the source of
DNA would be the cells that disintegrate by apoptosis
and/or necrosis in an expanding tumor tissue [16]. The
origin of the apoptotic and necrotic cells would relate
the presence of s/p DNA with the anaplasia and necrosis
that is frequently associated with bad prognostic factors
like high grade, non-differentiation, larger tumor and
advanced stage. Moreover, it would explain the presence
of DNA in tumors that infrequently give metastasis, as
glioblastoma multiforme, but have a high degree of
anaplasia and necrosis in spite of being confined to the
brain [17]. DNA could simply be released from cell
fragments of tumor tissue, which cross the blood-brain
barrier by the rich brain vascularization and reach the
blood stream but cannot metastasize to new organs. In
Figure 1, a methylation-specific PCR of MGMT, p16,
DAPK and RASSF1A done in serum and primary tumors
of glioblastoma multiforme patients is shown.
However, origin from apoptotic and necrotic DNA
would be difficult to explain in the case of earlier tumors
– of small size with a low necrosis pattern, or in cases
where tumor DNA is detected months before the
diagnosis of cancer. Hence, the origin of circulating DNA
remains unresolved.
Tu m o r  o r i g i n  o f  s / p  D N A
To date, several studies have reported the presence of
free DNA concentrations in the serum of cancer patients,
and molecular studies have provided evidence that this
DNA is similar to tumor DNA. A summary of different
studies is detailed in Table I. In all these studies, the
authors select patients with a particular cancer, individuals
described as healthy controls, and a molecular alteration
to be tested. Using PCR technology methods, the
alterations found in tissue samples of various neoplastic
diseases such as breast, head and neck, non-small- cell-
and small-cell lung cancers, pancreas, liver, colon, kidney,
esophagus, ovary, bladder, melanoma, and brain (glio-
blastoma) were definitely the same as the alterations
found in s/p for the same patients [5, 11, 17-39]. Control
healthy cases do not show any of the alterations found in
cancer patients, confirming the specificity of circulating
free DNA with neoplastic characteristics only in neoplastic
patients. The range of similarity between the data found in
tissue and serum/plasma is between 23-95%, with
a median value of 71%, which means that depending on
the specificity of a particular molecular alteration for
every particular tumor, the serum or plasma is a good
non-invasive method to study the alterations found in
tumors. A major problem with these studies is the still
low sensitivity of molecular analysis. The technique to
obtain DNA in serum or plasma is important. Some
authors have approached the issue of misinterpretations of
results that occur when DNA concentrations are under
the threshold of detection. PCR artifacts can mimic
genetic alterations, especially with techniques like
microsatellite analysis [40]. Therefore, s/p DNA must be
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analyzed with very sensitive and specific methods, such
as mutant allele specific amplifications that exclude
artifacts. When discrepancies exist between s/p DNA and
tumor DNA (especially when a positive value in plasma
is not found in tissue), good explanations could be:
a characterization in tumor failed because of an excessive
contamination of tumor tissue by normal cells, or because
a sub clone of tumor cells with the alteration could release
DNA in the plasma at higher concentrations compared to
other clones in the tumor [40].
Once a tumor origin is confirmed, new possibilities in
the monitoring of cancer can be foreseen. Several authors
Figure 1. Methylation-specific PCR of MGMT, p16, DAPK and RASSF1A
Genomic DNA was obtained from tissue samples using DNA easy tissue kit (Qiagen, Hilden, Germany).
Serum DNA was extracted using the QIAmp Blood Mini Kit (Qiagen). DNA methylation patterns in the CpG dinucleotides of MGMT (GenBank
accession number U95038), p16 (GenBank accession number X94154), DAPK (GenBank accession number NM_004938), and RASSF1A
(GenBank accession number XM_004938) were determined by MSP assay.
Bisulfite-treated DNA was purified using the Wizard DNA clean-up system (Promega Co., Madison, WI, USA).
Five µl of bisulfite-modified DNA was amplified by PCR using primers that were specific for methylated or unmethylated sequences of each gene.
T= Tumor DNA; S= Serum DNA; L= Lymphocyte DNA used as negative and positive control for methylated and unmethylated PCR reaction,
respectively; SW-48, HT-29, MOLT-4 cell lines and MP (in vitro SssI modified placental DNA) used as positive and negative control for methylated
and unmethylated PCR reaction respectively.
Table I: DNA alterations found in tumor and serum or plasma in different tumors
Tumor Alterations Patients / % Tumor % S/P vs Ref.
controls positive tumor
Breast LOH, P53, p16 methylation 62/17 90 73 5
Microsatellite instability, LOH 52/9 55 55 18
LOH 71/9 31.3 95 19
P53 126 36.5 65.1 20
Head and neck Methylation of p16, MGMT, GSTP1, DAP Kinase 95/25 55 42 21
Non-small cell lung Microsatellite alterations, FHIT 87/14 56 61 22
P16 methylation, MGMT, GSTP1, DAP Kinase 22/- 68 73 23
APC methylation 99/50 96 47 24
Microsatellite instability, LOH 5 17/31 59 70 25
Small cell lung Microsatellite alterations 21/- 76 71 26
Microsatellite instability 11/31 73 87 25
Pancreas K-ras 39/60 72 32 27
K-ras 21/4 71 60 28
Liver P16 Methylation 22/38 73 81 29
Mitochondrial D-loop mutations 19 68 80 30
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have considered this new tool to predict prognosis, to
monitor early recurrence as a tumor marker, or to be
used as an early diagnostic tool.
Va l u e  o f  s / p  a s  a P r o g n o s t i c  To o l
Tumor-specific genetic markers can be assessed primarily
in tumor biopsies. However, in advanced patients with
metastasis at diagnosis, surgery is not always performed so
the availability of tumor tissue for genetic assessment is
limited. The detection of tumor-specific genetic markers
at distant sites from the tumor, such as in the blood,
provides a unique and valuable tumor genetic marker
assay for diagnosis and prognosis. The presence of serum
DNA has been correlated with histological features of
tumor aggressiveness, and some alterations seem to be
a negative prognostic factor in some tumors [5, 6, 21, 24,
27, 28, 32, 34, 37, 38]. However, not all findings support
this relationship [22]. The studies that approached this
issue and have uncovered interesting relationships
between prognosis and s/p plasma alterations are
summarized in Table II. The sensitivity of the test for
diagnosis and prognosis purposes could be further
increased by obtaining a panel of positive markers capable
of detecting molecular changes in plasma DNA for each
tumor [41, 42]. The presence of s/p DNA in patients with
colorectal cancer has been associated with poor prognosis
regardless of the alteration detected [6].
The hypermethylations of the promoter region of
p14ARF have been identified as a prognostic factor in
bladder cancer [37]. This alteration, found in 56% of the
tumor samples and in 87% of paired analyzed serums,
was related to poor prognosis factors such as multi-
centricity, tumor size, bladder muscle invasion, and
higher stage. In breast cancer, one study showed that
the presence of circulating plasma DNA was a poor
prognostic factor associated significantly with ≥3 positive
nodes, ductal infiltrating carcinoma, high histological
index, and high proliferative Ki-67 index [5]. In another
work, the mean concentration of plasma DNA was found
to be 211ng/mL substantially different from the levels
found in healthy women (21ng/mL). Moreover, the
presence of p53 mutations in plasma was found to confer
a poor prognosis and was associated with larger tumors,
higher stage, lymph node involvement, and negative
receptor status (p<0.05). After a median follow-up of 29
months, multivariate analysis revealed that plasma DNA
p53 mutations were an independent factor of early relapse
and lower survival [20].
K-ras codon 12 mutations have been related to poor
prognosis in pancreatic cancer [27, 28]. In malignant
melanoma, a study of 10 microsatellite markers showed
at least one LOH in 85% of the 76 tumors studied, and
68% of patients repeated this alteration in plasma. A
significant relationship was found between the number of
microsatellite markers with LOH in plasma and a more
advanced clinical stage of the disease [38]. Only the LOH
of loci D33S1293 was significantly correlated to disease
progression.
In head and neck cancer, the hypermethylation of
the promoter region of DAP kinase in serum was related
to more affected lymph nodes and a more advanced stage
of the disease. Moreover, a tendency to present distant
metastasis in the case of hypermethylation was signaled
by the authors [21]. In colon cancer, the presence of
circulating tumor DNA has been identified as a poor
Table I (cont'd): DNA alterations found in tumor and serum or plasma in different tumors
Tumor Alterations Patients / % Tumor % S/P vs Ref.
controls positive tumor
Colon K-ras 14/- 50 86 31
P16 52/44 38 70 32
Renal cell LOH 3p 21/10 71 61 33
Microsatellite alterations 53/20 – 87 34
Esophagus P16 methylation 38/- 82 23 35
ErbB-2 amplification 31/10 31 83 36
Ovary LOH, microsatellite instability 20/8 56-63 73 11
Bladder LOH 27/- 56 63 37
Methylation of P14ARF 27/- 56 87 37
Melanoma LOH (10 loci) 40 85 68 38
Gastric Methylation of 54/30 39
DAP-Kinase 70.3 68.4
E Cadherin 75.9 75.6
GSTP1 18.5 80
P15 68.5 81.1
P16 66.7 77.8
Brain (GBM) Methylation 21 17
MGMT 28.6 83.3
P16 61.9 92.3
DAPK 38..1 100
RASS1A 52.4 91
T= Tumors; S/P= serum or plasma, GBM= glioblastoma multiforme
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prognostic factor, and specifically the hypermethylations
of the promoter region of p16INK4a in serum seems to
be related with an advanced stage[32]. In lung cancer,
the quantitative hypermethylations measure on tissue of
the adenomatous polyposis coli (APC) promoter 1A
mapped at the chromosome 5p21 have been related as an
independent factor with worse survival in 99 patients who
exhibit this methylation in their tissues in 95% of the
cases. Forty-two paired serum were also studied, but
exhibited a methylated pattern in only 47% of the cases
and the relationship on survival was not significant. Not
one of the 50 controls exhibited hypermethylation. The
authors attribute the lack of significance to the special
choice of samples they have done, and they concluded
that APC methylation in s/p analysis appears to be
a promising non-invasive tool as a prognostic factor in
primary lung cancer [24].
MGMT promoter methylation has been detected in
the serum of glioblastoma patients. This gene encodes
the enzyme O6 methyl-guanine-methyl transferase, which
removes the monofunctional O6 adduct from the DNA
produced by drugs commonly used in the treatment of
glioblastoma multiforme. When response to chemo-
therapy was broken down by methylation status in serum
only, objective response plus stable disease was seen in 8/8
(100%) patients with methylated bands, and in 7/17
(41.2%) with unmethylated bands (Fisher's exact test,
p=0.008). Therefore, the detection of hypermethylation
of MGMT promoter could be a good test to predict
chemotherapy response [17]. Microsatellite alterations
in s/p DNA have been related to a more advanced stage
in renal cancer [34].
Tumor progression is a dynamic event and the
genetic changes that concurrently occur are ongoing. The
most significant advantage of assessing plasma alterations,
compared with direct analysis of tumor biopsies, is the
ability to monitor disease progression and genetic changes
without assessing the primary tumor (i.e. to repeat the
biopsy) at different stages of the disease and along its
evolution. The identification of a panel of positive
markers for each tumor should be the first step in
designing prospective trials, in order to evaluate sensitivity
and specificity for prognostic purposes.
Va l u e  a s  a Fo l l o w - u p  To o l
The analysis of s/p DNA could be a good tool for
cancer screening. The disappearance of s/p DNA levels,
Table II. Studies that suggest s/p DNA has a value as a prognostic marker
Tumor Num patients Alteration Prognosis Ref.
Bladder 27 Methylation promoter p14ARF Poor 37
Multifocentric foci
Larger tumors
Relapse
Pancreas 21 K-ras codon 12 Poor 28
Larger tumors
Worse prognosis after surgery
39 K-ras codon 12 Poor 27
Stage
Metastasis
Breast 62 DNA plasma levels Poor 5
(LOH or p53 or p16INK4a) Nodes
Proliferative index
126 P53 Poor 20
Size
Stage
Node status
Estrogen receptor status
Melanoma 76 Number of LOH detected Poor 38
Stage
Head and Neck 95 Methylation Poor 21
DAP kinase promoter Lymph node
Stage
Colon 52 Methylation Poor 32
p16INK4a promoter Stage
58 pDNA present Poor
2 year overall survival 6
2 year recurrence
Brain (GBM) 21 MGMT methylation Good 17
More responses to BCNU therapy
Longer time to progression
Renal 53 Microsatellite alterations Poor 34
20 markers Stage
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the persistence of its levels after treatment, or the re-
appearance of the molecular alteration during follow-up,
could become fine tools to document how effective the
treatment is, and to follow up the patients without
invasive and expensive techniques.
Some studies, which are summarized in Table III,
have approached these objectives and interesting
observations have been made.
Sozzi et al. analyzed the levels of tumor DNA
using a DNA quantifications assay and molecular
characterization of tumor plasma DNA through the
analysis of microsatellite alterations [43]. In a previous
study, the authors have documented that 61% of non-
small cell lung cancer patients showed allele shift and
LOH at FHIT and other genomic loci in tumor samples,
and also in plasma irrespective of tumor size or stage,
suggesting that circulating DNA was associated with
early phases of lung cancer development [22]. They
subsequently discovered that the levels of DNA dropped
after surgery, in 1-6 months, to the levels of healthy
controls and that all patients with recurrent disease
showed an increase in levels of s/p DNA, suggesting a re-
growing tumor. Our group detected a patient with a stage
I lung cancer who presented persistent elevated levels of
serum DNA with microsatellite alterations after surgery
and developed systemic metastases on follow-up [44]. In
addition, in small cell lung cancer it has been possible to
correlate a good tumor response with the disappearance
of abnormal plasma DNA and the reappearance at the
moment of progression [45].
In esophageal cancer, erB-2 amplifications were
found in untreated patients but not in treated ones
[36]. Molecular alterations, such as LOH or p53 or
p16INK4a previously found in breast cancer [5], were found
to have follow-up implications. The persistence of these
alterations after mastectomy was associated with poor
prognostic characteristics, such as vascular invasion,
affected lymph nodes, and higher histological grade,
which are strong predictors of earlier recurrence and
lower survival [46]. Furthermore, a disappearance of the
plasma codon 12 K-ras mutation in pancreatic cancer in
pre- and post-surgical samples of 6 out of 9 patients
(67%) was observed, and 3 patients with persistently
positive mutation were likely to show early recurrence
or progressive disease [28]. Again, only prospective trials
will confirm these earlier results.
Va l u e  o f  s / p  D N A  f o r  E a r l y  D i a g n o s i s
Although the usefulness of this methodology to detect
micrometastatic disease in earlier phases of the disease
remains to be proved [19], circulating s/p DNA is
associated with the early phases of tumor development in
many tumors, and it has been suggested that it could be
useful as a tool for screening and for diagnosis [18, 19].
The goal would be to identify a useful test to be applied in
an asymptomatic population and to be used as a non-
invasive diagnostic procedure. Some studies suggest this
application and are summarized in Table III. Some
genetic alterations found in circulating DNA have been
suggested as good candidates for a marker of early
detection. For example, a selective mutation in codon
249 of the p53 gene has been identified as a hotspot in
liver cancer associated with the exposure to aflatoxins.
This tumor is a major cause of cancer death in Gambia.
The Gambian patients examined (53 cancer patients, 13
cirrhotic patients, and 53 healthy controls) presented this
mutation in their plasma at significantly different
frequencies. The test was strongly associated with liver
cancer in this population and could possibly be a good
marker for early diagnosis, to identify patients at risk.
Besides, none of the 16 French patients not exposed to
aflatoxins presented this mutation. Of course, a follow-up
control of positive non-cancer patients would be
compelling [47].
Plasma DNA alterations were detectable in 43% of
pathological stage I non-small-cell lung cancers, and in
45% of tumors up to 2 cm in diameter, which suggest
that an early detection by a non-invasive screening
procedure would be possible in a population at risk, such
Table III. Studies that suggest s/p DNA has value as a follow-up tool
Tumor Num patients Alteration Observations Ref.
Non-small cell lung 84 Microsatellite instability Surgical tumor free patients drop DNA levels, recurrence 43
LOH produces a reappearance of high levels of circulating DNA
22 3p Microsatellite 1 stage I patient with an abnormality was identified before 44
instability or LOH developing distant metastasis
Small cell lung 35 MI, p53 In 15 patients it was possible to find correlations between tumor 45
response and disappearance of abnormal plasma DNA or tumor 
progression
Esophagus 30 ErB-2 amplifications Elevated s/p DNA values if patient treated but 36
not in pre-treated
Breast 41 LOH or p53 or p16INK4a Persistence of molecular alterations after mastectomy 46
in patients with vascular invasion, affected nodes and higher 
histological grade
Pancreas 21 K-ras Treatment resulted in disappearance of K-ras mutation in 67% 28
of patients. Three patients with persistent levels showed early 
recurrence or progressive disease
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as heavy smokers [22]. LOH of diverse loci seem to have
a 41% sensitivity to detect lung cancer, and were present
in plasma several months before the cancer diagnosis
[49]. LOH as an early event in carcinogenesis has been
detected in cases of small breast tumors and in situ
carcinomas [31]. Curiously, K-ras mutations were found in
the plasma of 17 out of 21 patients with pancreatic cancer
(81%) and none in 8 healthy controls. In 4 patients, the
mutation was found 5 to 14 months before the diagnosis
of cancer while the patient was diagnosed with chronic
pancreatitis and biopsies were negative for tumor,
suggesting a role in the earlier diagnosis of this disease.
A later study with more cases determined that plasma
K-ras analysis was a highly specific but low sensitivity
approach for pancreatic cancer. The low sensitivity was
attributed to the fact that plasma K-ras mutation was
found in only 9 of the 28 patients (32%) that exhibited
this mutation in tissue, constituting 72% of the group of
39 pancreatic cancers [49].
An alteration that is found in only 9% of tumor
samples in affected patients, as is the case of mito-
chondrial DNA alterations at the D-loop region
(mtDNA) in colorectal cancer, would be a poor early
prognostic test, although it is possible to detect the same
alteration in the serum in 14% of the affected individuals
[50]. Larger studies are required to further assess the
relevance of these observations and to understand their
applicability to clinical practice.
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